Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0311 Transporter Info
Gene Name	SLC35F6
Transporter Name	ANT2-binding protein
Gene ID	54978
UniProt ID	Q8N357

Post-Translational Modification of This DT
Overview ofSLC35F6 Modification Sites with Functional and Structural Information
Sequence	M A W T K Y Q L F L A G L M L V T G S I N T L S A K W A D N F M A E G C G G S K E H S F Q H P F L Q A V G M F L G E F S C L A A F Y L L R C R A A G Q S D S S V D P Q Q P F N P L L F L P P A L C D M T G T S L M Y V A L N M T S A S S F Q M L R G A V I I F T G L F S V A F L G R R L V L S Q W L G I L A T I A G L V V V G L A D L L S K H D S Q H K L S E V I T G D L L I I M A Q I I V A I Q M V L E E K F V Y K H N V H P L R A V G T E G L F G F V I L S L L L V P M Y Y I P A G S F S G N P R G T L E D A L D A F C Q V G Q Q P L I A V A L L G N I S S I A F F N F A G I S V T K E L S A T T R M V L D S L R T V V I W A L S L A L G W E A F H A L Q I L G F L I L L I G T A L Y N G L H R P L L G R L S R G R P L A E E S E Q E R L L G G T R T P I N D A S
PTM type	X-N-glycosylation X-Phosphorylation X-S-palmitoylation X-SUMOylation X-Ubiquitination X: Amino Acid

N-glycosylation
Asparagine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC35F6			[1]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	110
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC35F6 Asparagine 110 has the potential to affect its expression or activity.
Phosphorylation
Serine	5 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC35F6			[2]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	24
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Serine 24 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC35F6			[3], [4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	237
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Serine 237 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC35F6			[3], [4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	239
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Serine 239 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC35F6			[5], [6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	354
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Serine 354 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC35F6			[7], [8]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	371
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Serine 371 has the potential to affect its expression or activity.
Threonine	5 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC35F6			[2]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	4
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Threonine 4 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC35F6			[2]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	17
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Threonine 17 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC35F6			[2]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	22
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Threonine 22 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC35F6			[9], [10]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	363
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Threonine 363 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC35F6			[10], [11]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	365
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Threonine 365 has the potential to affect its expression or activity.
Tyrosine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC35F6			[12]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	6
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC35F6 Tyrosine 6 has the potential to affect its expression or activity.
S-palmitoylation
Cystine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC35F6			[13]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	70
Experimental Method	Co-Immunoprecipitation
Detailed Description	S-palmitoylation at SLC35F6 Cystine 70 has the potential to affect its expression or activity.
SUMOylation
Lysine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	.			[14]
Role of PTM	Influencing the Disease Progression
Modified Residue	Lysine	Modified Location	150
Experimental Method	Co-Immunoprecipitation
Detailed Description	SUMOylation at SLC35F6 Lysine 150 have been reported to mediate its interaction with other proteins, and inhibition of this modification enhances therapeutic efficacy in pancreatic ductal adenocarcinoma (PDAC).
PTM Phenomenon2	.			[14]
Role of PTM	Influencing the Disease Progression
Modified Residue	Lysine	Modified Location	154
Experimental Method	Co-Immunoprecipitation
Detailed Description	SUMOylation at SLC35F6 Lysine 154 have been reported to mediate its interaction with other proteins, and inhibition of this modification enhances therapeutic efficacy in pancreatic ductal adenocarcinoma (PDAC).
Ubiquitination
Lysine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC35F6			[15], [16]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	199
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC35F6 Lysine 199 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC35F6			[16], [17]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	203
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC35F6 Lysine 203 has the potential to affect its expression or activity.

References
1	dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: S35F6_HUMAN)
2	TiO2 with Tandem Fractionation (TAFT): An Approach for Rapid, Deep, Reproducible, and High-Throughput Phosphoproteome Analysis. J Proteome Res. 2018 Jan 5;17(1):710-721.
3	Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target. Nat Commun. 2018 Sep 11;9(1):3679.
4	Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer. Int J Cancer. 2019 Feb 1;144(3):545-557.
5	Determination of Site-Specific Phosphorylation Ratios in Proteins with Targeted Mass Spectrometry. J Proteome Res. 2018 Apr 6;17(4):1654-1663.
6	Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells. Mol Cell Proteomics. 2018 Apr;17(4):550-564.
7	Capillary Zone Electrophoresis-Tandem Mass Spectrometry for Large-Scale Phosphoproteomics with the Production of over 11,000 Phosphopeptides from the Colon Carcinoma HCT116 Cell Line. Anal Chem. 2019 Feb 5;91(3):2201-2208.
8	Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells. Biochem Biophys Res Commun. 2018 Oct 20;505(1):187-193.
9	Global Landscape and Dynamics of Parkin and USP30-Dependent Ubiquitylomes in iNeurons during Mitophagic Signaling. Mol Cell. 2020 Mar 5;77(5):1124-1142.e10.
10	Quantitative Phosphoproteome Analysis of Clostridioides difficile Toxin B Treated Human Epithelial Cells. Front Microbiol. 2018 Dec 17;9:3083.
11	Robust, Reproducible, and Economical Phosphopeptide Enrichment Using Calcium Titanate. J Proteome Res. 2019 Mar 1;18(3):1411-1417.
12	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14;131(6):1190-203.
13	Selective Enrichment and Direct Analysis of Protein S-Palmitoylation Sites. J Proteome Res. 2018 May 4;17(5):1907-1922.
14	SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma. Mol Cell Biol. 2021;41(12):e0013521.
15	Systematic functional prioritization of protein posttranslational modifications. Cell. 2012 Jul 20;150(2):413-25.
16	Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol. 2012 Oct;14(10):1089-98.
17	Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature. 2021 Jun;594(7862):246-252.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence